Emergent BioSolutions Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Total Revenues of $293.8 million , increase of 9% versus prior year Third Quarter 2024 Net Income of $114.8 million , increase of 144% versus prior year Third Quarter 2024 Adjusted...
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md. , Nov....
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
GAITHERSBURG, Md. , Oct. 23, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern...
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety measures One-year mark of Ready to Rescue public awareness campaign to expand...
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
GAITHERSBURG, Md. , Oct. 02, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an...
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
GAITHERSBURG, Md. , Sept. 26, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure...
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 GAITHERSBURG, Md. , Sept. 25, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS)...
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
GAITHERSBURG, Md. , Sept. 13, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md. , Sept. 12, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by...
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company GAITHERSBURG, Md. , Sept. 03, 2024 (GLOBE...
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
For the second year, Emergent is teaming up with pro football legend, Emmitt Smith , to educate communities on opioid risks and how to be prepared with NARCAN ® Nasal Spray In recognition of...
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
GAITHERSBURG, Md. , Aug. 29, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the...